GAITHERSBURG, Md., Aug. 05, 2025 (GLOBE NEWSWIRE) — Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company, today announced that it will report its second quarter 2025 financial results on Tuesday, August 12, 2025. Altimmune management will host a conference call at 8:30 am E.T. on August 12 to discuss financial results and provide a business update. The conference call will be webcast live on Altimmune's Investor Relations website at https://ir.altimmune.com/investors. Participants who would like to join the call may register here to receive the dial-in numbers and unique PIN to access the call. Shortly after the call, a replay will be available on the Investor Relations website for up to three months. About Altimmune Altimmune is a late clinical-stage biopharmaceutical company focused on developing novel peptide-based therapeutics for liver and cardiometabolic diseases. The Company's lead program is pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH), Alcohol Use Disorder (AUD), Alcohol-Associated Liver Disease (ALD) and obesity. For more information, please visit www.altimmune.com. Follow @Altimmune, Inc. on LinkedIn Company Contact: Investor Contact: Media Contact: This press release was published by a CLEAR(R) Verified individual.
Follow @AltimmuneInc on X
Greg Weaver
Chief Financial Officer
Phone: 240-654-1450
ir@altimmune.com
Lee Roth
Burns McClellan
Phone: 646-382-3403
lroth@burnsmc.com
Jake Robison
Inizio Evoke, Biotech
Phone: 619-849-5383
Jake.robison@inizioevoke.com
